Recap: Amicus Therapeutics Q3 Earnings

Amicus Therapeutics FOLD reported its Q3 earnings results on Monday, November 7, 2022 at 06:12 AM.

Here's what investors need to know about the announcement.

Earnings

Amicus Therapeutics beat estimated earnings by 36.84%, reporting an EPS of $-0.12 versus an estimate of $-0.19.

Revenue was up $2.15 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.01 which was followed by a 11.33% increase in the share price the next day.

Here's a look at Amicus Therapeutics's past performance:

 

Quarter Q2 2022 Q1 2022 Q4 2021 Q3 2021
EPS Estimate -0.22 -0.25 -0.16 -0.18
EPS Actual -0.21 -0.30 -0.29 -0.19
Revenue Estimate 85.89M 77.13M 83.28M 80.11M
Revenue Actual 80.73M 78.72M 82.15M 79.55M

To track all earnings releases for Amicus Therapeutics visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Posted In: BZI-RecapsEarnings